Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1718results about "Bacteriophages" patented technology

Sequence-specific antimicrobials by blocking DNA repair

The invention relates to the improvement of endonuclease-based antimicrobials by blocking DNA repair of double-strand break(s) (DSB(s)) in prokaryotic cells. In this respect, the invention especially concerns a method involving blocking DNA repair after a nucleic acid has been submitted to DSB, in particular by a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated programmable double-strand endonuclease. The invention particularly relates to the use of an exogenous molecule that inhibits DNA repair, preferably a protein that binds to the ends of the double-stranded break to block DSB repair. The invention also relates to vectors, particularly phagemids and plasmids, comprising nucleic acids encoding nucleases and Gam proteins, and a pharmaceutical composition and a product containing these vectors and their application.
Owner:INST PASTEUR +1

Altering microbial populations and modifying microbiota

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.
Owner:SNIPR TECH

Pharming bacteriophage and application thereof

The invention provides a virulent bacteriophage and application thereof, the virulent bacteriophage is named as vBVpaPChan1 and has been preserved in China Center for Type Culture Collection on December 10, 2024, the preservation address is Wuhan University, Wuhan, Hubei, China, and the preservation number is CCTCC M 20242772. The bacteriophage is safe, environmentally friendly and free of toxic and side effects, and compared with known bacteriophages, the bacteriophage is short in incubation period, large in outbreak amount and capable of effectively killing diseases caused by vibrio parahaemolyticus chan02.
Owner:WUHAN INST OF TECH

Novel acinetobacter baumannii phage vBAbaSqsb1 and application thereof

The invention discloses a novel acinetobacter baumannii phage vBAbaSqsb1 and application thereof, and belongs to the technical field of microorganisms. The bacteriophage is an Acinetobacter baumannii bacteriophage vBAbaSqsb1 which is preserved in the Guangdong Microbiological Culture Collection Center on July 5, 2024, the preservation number is GDMCC (China General Microbiological Culture Collection Center) NO: 64831-B1, and the preservation address is Institute of Microbiology of Academy of Sciences of Guangdong Province. The bacteriophage can specifically recognize and split the acinetobacter baumannii so as to eliminate infection and overcome the problem of antibiotic resistance of the acinetobacter baumannii. Through discovery and application research of the phage vBAbaSqsb1, the phage vBAbaSqsb1 not only can be used for preparing a phage preparation for preventing and treating diseases caused by acinetobacter baumannii infection, but also can be used for preparing various environmental bactericides for solving potential acinetobacter baumannii in various environments. The bacteriophage vBAbaSqsb1 has the characteristics of safety, no toxic or side effect and the like, so that the problem of drug resistance caused by abuse of antibiotics can be avoided when the bacteriophage vBAbaSqsb1 is applied.
Owner:MENGCHAO HEPATOBILIARY HOSPITAL OF FUJIAN MEDICAL UNIV

Lytic bacteriophage vBVcaPR25D and application thereof

The invention discloses a lytic bacteriophage vBVcaPR25D and an application of the lytic bacteriophage vBVcaPR25D. The collection number of the lytic bacteriophage vBVcaPR25D is GDMCC (Graphical Digital Microbial Culture Collection Center) No: 65167-B1. The lytic bacteriophage vBVcaPR25D provided by the invention has a high specificity and a remarkable killing effect on vibrio cantoniensis V.campbelli LMG 11216T, and can be used for killing vibrio cantoniensis V.campbelli LMG 11216T. Besides, virulence factor genes and drug-resistant genes are not detected in the genome of the bacteriophage, so that the bacteriophage is high in safety and environment-friendly, and can be used as a bactericide for aquatic vibrio candersonii diseases.
Owner:SHENZHEN UNIV

Pharming bacteriophage vBValSR36H with host being vibrio alginolyticus and application thereof

The invention discloses a virulent bacteriophage vBValSR36H with a host being vibrio alginolyticus and application of the virulent bacteriophage vBValSR36H, and relates to the technical field of microbial control. The invention provides a bacteriophage capable of efficiently cracking Vibrio alginolyticus ATCC 17749T, the bacteriophage is named as vBValSR36H, the preservation number is 66248-B1, and the preservation address is Institute of Microbiology, Academy of Sciences in Guangdong Province. The vibrio alginolyticus bacteriophage vBValSR36H provided by the invention has good environmental stability and certain bactericidal activity, and has a relatively wide environmental adaptation range and relatively long survival time. The bacteriophage vBValSR36H provided by the invention can specifically and effectively kill, prevent and control related vibrio diseases, meanwhile, virulence factor genes and drug-resistant genes are not detected in the bacteriophage, and the bacteriophage vBValSR36H has the advantages of no toxic or side effect, high safety, environmental friendliness and wide application prospect. Therefore, the vibrio alginolyticus bacteriophage vBValSR36H can be completely applied to killing and / or preventing vibrio alginolyticus for non-disease diagnosis and treatment purposes.
Owner:SHENZHEN FEITAI BIOTECHNOLOGY CO LTD

Altering microbial populations & modifying microbiota

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.
Owner:SNIPR TECH

Lytic bacteriophage vBVcaPR24D and application thereof

The invention discloses a lytic bacteriophage vBVcaPR24D and an application of the lytic bacteriophage vBVcaPR24D. The collection number of the lytic bacteriophage vBVcaPR24D is GDMCC (Graphical Digital Microbial Culture Collection Center) No: 65166-B1. The lytic bacteriophage vBVcaPR24D provided by the invention has a high specificity and a remarkable killing effect on vibrio cantoniensis V.campbelli LMG 11216T, and can be used for killing vibrio cantoniensis V.campbelli LMG 11216T. Besides, virulence factor genes and drug-resistant genes are not detected in the genome of the bacteriophage, so that the bacteriophage is high in safety and environment-friendly, and can be used as a bactericide for aquatic vibrio candersonii diseases.
Owner:SHENZHEN UNIV

Altering microbial populations & modifying microbiota

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.
Owner:SNIPR TECH

Self-assembling virus-like particles for delivery of prime editors and methods of making and using same

The present disclosure provides virus-like particles (VLPs) for delivering prime editors, and systems comprising such prime editor (PE) VLPs. The present disclosure also provides polynucleotides encoding the PE-VLPs described herein, which may be useful for producing said PE-VLPs. Also provided herein are methods for editing the genome of a target cell by introducing the presently described PE-VLPs into the target cell. The present disclosure also provides fusion proteins that make up a component of the PE-VLPs described herein, as well as polynucleotides, vectors, cells, and kits.
Owner:THE BROAD INST INC

Stenotrophomonas maltophilia phage, composition and application thereof

The invention discloses stenotrophomonas maltophilia bacteriophage, a composition and application thereof. Relates to the technical field of biology, the stenotrophomonas maltophilia bacteriophage comprises a bacteriophage vBSma-SZP9, the taxonomic name of the bacteriophage vBSma-SZP9 is Snotrophomonas phage, the Latin literature name of the bacteriophage vBSma-SZP9 is Snotrophomonas phage, the bacteriophage vBSma-SZP9 is preserved in the Guangdong Microbiological Culture Collection Center, the preservation address is the fifth floor of the building 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou, the preservation number is GDMCC No: 64509-B1, and the preservation date is May 16, 2024. The bacteriophage disclosed by the invention is wide in host spectrum, strong in infection ability and wide in temperature and acid-base tolerance range.
Owner:SHENZHEN NAT CLINICAL RES CENT FOR INFECTIOUS DISEASES +1

Cracking bacteriophage vBVpaSR40Z and application thereof in prevention and control of vibrio parahaemolyticus in aquaculture environment

The invention discloses a lytic bacteriophage vBVpaSR40Z and application of the lytic bacteriophage vBVpaSR40Z to prevention and control of vibrio parahaemolyticus in an aquaculture environment. The preservation number of the vibrio parahaemolyticus phage vBVpaSR40Z is as follows: GDMCC No: 67440-B1, and the vibrio parahaemolyticus phage vBVpaSR40Z is The R40Z can be used for cracking multiple strains of vibrio parahaemolyticus and vibrio alginolyticus, has the capability of adapting to an aquaculture environment, and keeps relatively high activity within the range of 4-25 DEG C and pH of 4-10; no virulence gene or drug-resistant gene is detected through genome analysis, and phylogenetic and whole genome comparison shows that the similarity between R40Z and a related phage is lower than a species level threshold value, so that R40Z is a new phage species; the R40Z can obviously inhibit the growth of a host under various infection complex numbers. The R40Z has the advantages of strong splitting capacity, good environmental stability, high genome safety, unique evolutionary characteristics and the like, and is an aquatic vibriosis biological prevention and control bacteriophage with application potential.
Owner:SHENZHEN UNIV

Escherichia coli bacteriophage PEC-36 with cross-species host characteristic and application thereof

The invention discloses an Escherichia coli bacteriophage PEC-36 with cross-species host characteristics and application of the Escherichia coli bacteriophage PEC-36, and belongs to the technical field of biology. The Escherichia coli bacteriophage PEC-36 is separated from sewage of a pig factory, can simultaneously split O8: H7, O21: H34, O23: H16, O25: H4, O81: H27 and H25 serotype strains of Escherichia coli and fowl typhoid, London, swine cholera and other serotype strains of salmonella, and has a cross-species splitting characteristic. Experiments prove that the bacteriophage has the advantages of high titer, high stability, high safety and the like, and can remarkably inhibit the growth of escherichia coli and salmonella, so that a technical support is provided for research and development of bacteriophage preparations for treating infection related to escherichia coli and salmonella; the invention provides a safe and efficient antibiotic alternative scheme for treating human and animal Escherichia coli and salmonella related infection, and has a good application prospect.
Owner:HENAN AGRICULTURAL UNIVERSITY +1

Lysing bacteriophage for preventing and controlling vibrio in aquaculture environment

The invention discloses a lytic bacteriophage for preventing and controlling vibrio in an aquaculture environment. The bacteriophage vBValMR42H belongs to a muscle tail bacteriophage and is insensitive to chloroform, the capsid of the bacteriophage vBValMR42H is free of lipid substances, and the preservation number is GDMCC No: 67434-B1. The bacteriophage has the characteristics of high adsorption speed, short incubation period and high cracking amount, keeps high activity in a wide range of temperature (4-55 DEG C) and pH (2-11), and has strong environmental adaptability. Genome analysis shows that the bacteriophage does not contain virulence factors, antibiotic resistance genes and lyogen related genes, and is high in biological safety. Physical development analysis shows that the method can be divided into a new genus. The bacteriophage R42H has the advantages of high splitting efficiency, good environmental stability, strong specificity, gene safety and the like, and can be used as an ideal biological prevention and control agent for preventing and controlling vibrio alginolyticus diseases in aquaculture.
Owner:SHENZHEN UNIV

Phage for splitting escherichia coli high-risk clone strain and targeting multiple serotypes and application

The invention relates to the technical field of microorganisms, in particular to a bacteriophage capable of splitting a high-risk escherichia coli clone strain and targeting multiple serotypes and application of the bacteriophage. The invention discloses a bacteriophage capable of splitting a high-risk escherichia coli clone strain and targeting multiple serotypes, the bacteriophage is named as Escherichia phage vBEcoM32M3Y, the bacteriophage is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.45969. The invention further discloses a preparation method of the bacteriophage. The bacteriophage disclosed by the invention is low in MOI, good in stability, good in cracking activity, free of drug-resistant and virulence genes in a genome sequence, and relatively good in clinical application value.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

Circular RNA vaccines against SARS-COV-2 variants and methods of use thereof

Provided are circular RNAs (circRNAs) encoding an antigenic polypeptide of a SARS-CoV-2 variant. Provided are circRNA vaccines against a SARS-CoV-2 variant, such as a Delta or Omicron variant. The circRNA vaccine comprises a circRNA comprising a nucleic acid sequence encoding an antigenic polypeptide comprising a Spike(S) protein or a fragment thereof of a SRAS-CoV-2 variant. Also provided are methods of treating or preventing a SARS-CoV-2 infection using the circRNAs or compositions thereof.
Owner:PEKING UNIV

Riemerella anatipestifer phage and application thereof

The invention belongs to the technical field of microorganisms, and relates to a riemerella anatipestifer phage and application thereof. The riemerella anatipestifer bacteriophage provided by the invention is RA-XHX1, is preserved in the China Center for Type Culture Collection (CCTCC), has the preservation number of CCTCC NO: M 20241268, and is classified and named as the riemerella anatipestifer bacteriophage. The bacteriophage is double-stranded DNA (Deoxyribose Nucleic Acid) and myuroviridae, can form transparent plaques on a solid culture medium, has no halo ring around and is clear and regular in edge; the bacteriophage has a relatively good killing effect on riemerella anatipestifer in a space environment, particularly high-pathogenicity riemerella anatipestifer, and can realize a broad-spectrum antibacterial effect when being applied to preparation of medicines for preventing and treating riemerella anatipestifer infection.
Owner:SHANDONG NEW AIRLINE BIOTECHNOLOGY CO LTD

Bacteriophage for specifically lysing high-virulence capsular klebsiella pneumoniae, bacteriophage liquid formulation, and use thereof

A bacteriophage for specifically lysing high-virulence capsular Klebsiella pneumoniae, pertaining to the field of microorganisms. The deposit number of the Klebsiella pneumoniae bacteriophage vB_kpnP_D39 is CCTCC NO: M 2024690. In the bacteriophage liquid formulation prepared on the basis of the bacteriophage, the working titer of the bacteriophage is greater than 1 × 109 PFU / mL. The bacteriophage has high specificity and can kill all high-virulence multidrug-resistant Klebsiella pneumoniae of K1, K2, and K57 capsular serotypes, with an adsorption efficiency of 99.60%. The bacteriophage exhibits a biofilm clearance rate of 47.4%-63.2% and a capsule clearance rate of 42.1%-60.6% against the high-virulence Klebsiella pneumoniae. The bacteriophage is expected to become a safe, non-toxic agent for the prevention, control, and treatment of high-virulence multidrug-resistant Klebsiella pneumoniae infections, or an antibiotic adjuvant.
Owner:HEFEI UNIV OF TECH

Phage for fish nocardia and application thereof

PendingCN120989014ABiocideAntibacterial agentsBacteriophage tailMicroorganism
The invention relates to the technical field of bacteriophages, and provides a bacteriophage for fish nocardia and application of the bacteriophage, the bacteriophage is used for splitting fish nocardia, and the fish nocardia comes from a water body of a fish culture pond; the bacteriophage is preserved in China General Microbiological Culture Collection Center (CGMCC) on June 17, 2025, and the preservation number is CGMCC No.46495; the bacteriophage belongs to a tail bacteriophage, and the tail length is 165 + / -2nm. According to the technical scheme, the problem that at present, no bacteriophage for effectively treating and preventing fish nocardia exists is solved.
Owner:GUANGDONG OCEAN UNIVERSITY +2

High-temperature-resistant klebsiella pneumoniae bacteriophage as well as composition and kit thereof

The invention discloses a high-temperature-resistant klebsiella pneumoniae phage, a composition of the high-temperature-resistant klebsiella pneumoniae phage and a kit, the high-temperature-resistant klebsiella pneumoniae phage is klebsiella pneumoniae phage P6AKPJS20, the preservation number of the high-temperature-resistant klebsiella pneumoniae phage is CCTCC (China Center For Type Culture Collection) NO: M20242965, and the high-temperature-resistant klebsiella pneumoniae phage has a nucleotide sequence as shown in SEQ ID No.1-6. The bacteriophage has broad-spectrum bactericidal ability, wide acid-base tolerance range and certain tolerance to chloroform and diethyl ether, and can still maintain high activity while splitting target bacteria; meanwhile, the bacteriophage has good tolerance to high temperature and can adapt to various application conditions in production.
Owner:EMMEFEI (NANJING) BIOTECHNOLOGY CO LTD

Altering microbial populations & modifying microbiota

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.
Owner:SNIPR TECH

Vibrio candersonii bacteriophage composition with efficient antibacterial ability and application thereof

PendingCN119082046Aefficient lysisAvoid growth "rebound"BiocideClimate change adaptationBiotechnologyMarine aquaculture
The invention provides a vibrio candersonii bacteriophage, a bacteriophage composition and application thereof, and belongs to the technical field of microbial control. According to the invention, two new strains of strong vibrio canicola bacteriophages are obtained through screening, have strong host specificity and strong cracking and killing effects on vibrio canicola, and can effectively prevent vibrio canicola from generating resistance mutation when being mixed for use, so that an ideal pathogen removal effect is achieved, and the vibrio canicola bacteriophage has a good application prospect. Therefore, the method has important application value in the aspect of prevention and control of vibrio candersonii infectious diseases of marine aquaculture animals.
Owner:QINGDAO INST OF BIOENERGY & BIOPROCESS TECH CHINESE ACADEMY OF SCI +1

Methods and products for evolving genes

PCT designated stage expiredWO2024240906A1Virus peptidesTransferasesBiotechnologyDNA replication
The invention relates to cells comprising orthogonal DNA replication machinery, linear plasmids that may be replicated by said machinery, uses of said cells and said linear plasmids, methods of maintaining linear plasmids in cells, methods of evolving sequences of interest, and methods of making polypeptides or nucleic acids. The invention also relates to error-prone DNA polymerases, nucleic acids encoding said polymerases, and uses thereof.
Owner:UNITED KINGDOM RESEARCH AND INNOVATION

Continuous directed evolution

The invention provides systems, methods, reagents, apparatuses, vectors, and host cells for the continuous evolution of nucleic acids. For example, a lagoon is provided in which a population of viral vectors comprising a gene of interest replicates in a stream of host cells, wherein the viral vectors lack a gene encoding a protein required for the generation of infectious viral particles, and wherein that gene is expressed in the host cells under the control of a conditional promoter, the activity of which depends on a function of the gene of interest to be evolved. Some aspects of this invention provide evolved products obtained from continuous evolution procedures described herein. Kits containing materials for continuous evolution are also provided.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Staphylococcus bacteriophage and uses thereof

A composition comprising at least two different strains of isolated bacteriophages, each capable of infecting a bacteria of the species Staphylococcus aureus, wherein at least one of said at least two different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% identical to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-7. Uses thereof are also disclosed.
Owner:BIOMX LTD

Klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 and application thereof

The invention discloses a klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 and application thereof, and relates to the technical field of biology. The klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 is preserved in Guangdong Microbial Culture Collection Center on October 14, 2024, the preservation address is the 5th floor of the building 59, No.100 Courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No: 65268-B1. The bacteriophage keeps stable titer in a wide pH range (4-10) and a temperature interval (4-50 DEG C), and the highest titer can reach more than 109 pfu / mL. The bacteriophage can efficiently split klebsiella pneumoniae. The invention provides powerful technical support for developing novel antibacterial drugs and treatment schemes for klebsiella pneumoniae, and shows wide application prospect and potential clinical value.
Owner:GUANGZHOU MEDICAL UNIV

Carbapenem-resistant klebsiella pneumoniae bacteriophage and application thereof

According to the carbapenem-resistant klebsiella pneumoniae bacteriophage and the application, biological characteristic research, morphological analysis and other analysis are carried out on the bacteriophage, and it is found that the bacteriophage has a wide application prospect as a novel potential therapeutic agent and bactericide; meanwhile, the invention also provides a new feasible method for infection control and related application of clinical carbapenem-resistant klebsiella pneumoniae by researching the in-vitro synergistic effect of the klebsiella pneumoniae after the klebsiella pneumoniae is combined with carbapenem antibiotic meropenem.
Owner:THE SECOND HOSPITAL OF TIANJIN MEDICAL UNIV